News >

BTK and BCL-2 Inhibitors Reach New Milestones in CLL

Michael Choi, MD
Published: Wednesday, Feb 26, 2020

Michael Choi, MD, an associate clinical professor of medicine at the University of California, San Diego (UCSD) Medical Center

Michael Choi, MD,

Long-term data with BTK- and BCL-2–based treatment regimens have solidified their roles as standard frontline treatments for patients with chronic lymphocytic leukemia (CLL), and have set the stage for additional research aimed at delivering sustained remissions, according to Michael Choi, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication